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ProtocolSummary In some tumors, phosphatase and tensin homolog (PTEN) inactivation may have prognostic
importance and predictive value for targeted therapies. Immunohistochemistry (IHC) may be an
effective method to demonstrate PTEN loss. It was claimed that PTEN IHC showed poor
reproducibility, lack of standardization, and variable effects of preanalytical factors. In this study, we
developed an optimal protocol for PTEN IHC, with clone 6H2.1, by checking the relevance of analytical
variables in normal tissue and tumors of endometrium, breast, and prostate. Pattern and intensity of
cellular staining and background nonspecific staining were quantified and subjected to statistical
analysis by linear mixed models. The proposed protocol showed a statistically best performance (P b
.05) and included a high target retrieval solution, 1:100 primary antibody dilution (2.925 mg/L), FLEX
diluent, and EnVisionFLEX+ detection method, with a sensitivity and specificity of 72.33% and
78.57%, respectively. Staining specificity was confirmed in cell lines and animal models. Endometrial
carcinomas with PTEN genetic abnormalities showed statistically lower staining than tumors without
alterations (mean histoscores, 34.66 and 119.28, respectively; P = .01). Controlled preanalytical factors
(delayed fixation and overfixation) did not show any statistically significant effect on staining with
optimal protocol (P N .001). However, there was a trend of significance for decreased staining and
fixation under high temperature. Moreover, staining was better in endometrial aspirates than in matched☆☆ Conflict of interest: The study was done according to the research collaboration with Dako Denmark A/S. The sponsor did not participate in
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523A protocol for PTEN immunostaininghysterectomy specimens, subjected to less controlled preanalytical variables (mean histoscores, 80 and
40, respectively; P = .002). A scoring system combining intensity of staining and percentage of positive
cells was statistically associated with PTEN alterations (P = .01).
© 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Phosphatase and tensin homolog (PTEN) is frequently
somatically mutated or deleted in tumors [1]. Among other
activities, PTEN antagonizes the phosphoinositide 3 kinase/
alpha serine-threonine kinase (PI3K/AKT) pathway by
dephosphorylating PIP3, resulting in a decreased transloca-
tion of AKT to cellular membranes [2,3]. PTEN can be
inactivated by several different mechanisms, including gene
mutation, deletion, epigenetic silencing, transcriptional
repression, micro-RNA regulation, disruption of competi-
tive endogenous RNA networks, posttranslational modifi-
cations, and aberrant PTEN localization [4]. PTEN/PI3K
pathway activation may be a strong biological correlate of
metastasis and poor prognosis in some tumors [5-7].
Moreover, a new functional role for PTEN in genomic
instability has been proposed [4] suggesting that PARP
(poly ADP ribose polymerase) inhibitors may be useful in
patients with PTEN mutant tumors [8]. Furthermore, PTEN
expression has also been related to response to several drugs
in anticancer targeted therapies [9-11]. It has been suggested
that immunohistochemistry (IHC) may be an effective
method to demonstrate loss of PTEN function, but some
variability and poor reproducibility have been observed with
different antibodies and techniques [12-16].
In this study, we optimized a protocol for PTEN IHC and
assessed the impact of analytical and preanalytical factors, to
check the usefulness of IHC as a method for evaluation of
PTEN alterations. We assessed these variables in 3 tissues
(endometrium, breast, and prostate), in which PTEN is
expressed in normal cells and frequently abnormal in tumor
cells. The optimal protocol was tested in cell lines and animal
models as well as in tumors with known molecular status of
in PTEN.2. Materials and methods
2.1. Case selection and tissue microarray
construction
Five tissue microarrays (TMAs) were constructed from
formalin-fixed, paraffin-embedded (FFPE) tissue, corre-
sponding to normal prostate (PN; 30 cases), prostatic
carcinoma (PC; 30 cases), normal breast tissue (BN; 30
cases), breast carcinoma (BC; 30 cases), normal endome-
trium (30 cases), and endometrial carcinoma (EC; 45
cases). Samples were obtained from the surgical pathologyfiles of Hospital Universitari Arnau de Vilanova, Lleida,
Spain (HUAV). The study was approved by the local ethics
committee. Informed consent was obtained from each
patient. A tissue arrayer device (Beecher Instrument, Sun
Prairie, WI, USA) was used. All tissue samples were
histologically reviewed by 3 members of the team, and
representative tumor or nontumor areas were marked in the
corresponding paraffin blocks. Two selected cylinders (0.6
mm in largest diameter) from 2 different tumor or
nontumor areas were included for each case.
2.2. Tissues for assessment of preanalytical
variables
Eight surgical specimens were used, obtained from the
pathology files of HUAV. Three of them corresponded to
hysterectomy specimens for EC, 4 were breast excisions for
BC, and 1 was a partial prostatectomy for prostatic
hyperplasia. They were obtained from the operating room,
immediately after resection, and were selected because the
size of the specimens allowed obtaining a high number of
small fragments to check all possible combinations of the
controlled, preanalytical variables. The tissue was obtained
from the exceeding material, after having selected tissue
samples for appropriate diagnosis. The influence of addi-
tional, uncontrolled, preanalytical variables was also
checked in 4 TMAs constructed from FFPE tissues
corresponding to matched endometrial aspirates and hyster-
ectomy specimens. These tissues had been collected from a
total of 100 patients with EC, from the surgical pathology
files of HUAV. The study was approved by the local ethics
committee. Informed consent was obtained from each
patient. Although preanalytical conditions were not con-
trolled in these cases, this material was considered interesting
for assessing the influence of uncontrolled preanalytical
factors because endometrial aspirates are usually immersed
in formalin, immediately after being obtained while
hysterectomy specimens are usually subjected to variable
conditions of delayed fixation and time fixation.
2.3. Case selection for validation
We used 2 different series of EC with known PTEN
molecular status. One of them corresponded to 33 cases,
from Hospital Santa Creu i Sant Pau, included in a TMA,
which had been previously assessed for PTEN alterations, by
mutation, promoter hypermethylation, and loss of heterozy-
gosity (LOH) analyses [6]. The second series corresponded
524 O. Maiques et al.to 32 cases, which have been previously evaluated for
genomic copy number gene alterations by high-resolution
single nucleotide polymorphism (SNP) microarray, obtained
from the surgical pathology files of HUAV (manuscript
in preparation). Whole FFPE sections were available for
each of these cases. Informed consent was obtained from
each patient.
2.4. Cells lines
Three different human EC cell lines were used as controls
for IHC. The Ishikawa 3-H-12 (IK) cell line was obtained
from the American Type Culture Collection (Manassas,
VA). RL-95/2 (RL) and HEC-1-A (HEC) cells were a gift
from Dr Reventos (Hospital Vall d’Hebron, Barcelona,
Spain). Two of them have abnormalities in PTEN (IK and
RL-95-2), whereas the third (HEC) contains wild-type
PTEN. IK cells [17] contain 2 frameshift mutations in
PTEN. RL-95-2 is derived from a grade 2 moderately
differentiated adenosquamous EC [18] and produces a
mutated PTEN protein. To generate appropriate positive
and negative controls, IK and RL-95-2 were transfected with
exogenous PTEN, whereas HEC was subjected to PTEN
Knock-down. IK and RL 95/2 cells were transfected with a
plasmid containing complementary DNA for PTEN (PRK5-
PTEN) or the empty vector (PRK5) using polyethylenimide
reagent. On the other hand, lentiviral-based vectors for RNA
interference-mediated gene silencing (FSVsi) consisted of an
U6 promoter for expression of short-hairpin RNAs
(shRNAs) and the Venus variant of YFP under the control
of an SV40 promoter for monitoring transduction efficiency.
Samples were harvested by trypsinization and embedded in
1% agarose in phosphate-buffered saline, fixed in neutral
buffered formalin for 12 hours, and embedded in paraffin. At
the end, we had 6 different cell line controls. Three of them
were used as negative controls (IK, RL-95-2, that do not
express PTEN protein, and HEC subjected to PTEN
silencing by shRNA PTEN), and 3 were used as positive
controls (HEC that expresses PTEN protein, and IK and RL-
95-2 cell lines after overexpressing PTEN by transfection
with PTEN complementary DNA).
2.5. Animal tissues
Three different animal models were used: first, PTEN+/+
mice, with 2 normal copies of PTEN; second, PTEN+/−
mice, which have deletion of 1 copy of PTEN and develop
endometrial hyperplasia in 100% of cases and EC in 20% of
the cases [19]; finally, a novel conditional and inducible
PTEN−/− mouse model, which was recently developed by
our group [20], with PTEN deletion of the 2 alleles, mainly
in epithelial endometrial cells, but not in stromal cells, and
development of EC in 100% of the cases. Five animals of
each model were euthanized by cervical dislocation, and
uteri were collected. FFPE tissue was subjected to IHC.2.6. Immunohistochemistry
TMA blocks and whole-section FFPE blocks were
sectioned at a thickness of 3 μm, dried for 1 hour at 65°C,
deparaffinized, rehydrated, and subjected to target retrieval in
the pretreatment module, PTLINK (Dako, Glostrup, Den-
mark) at 95°C for 20 minutes in target retrieval solution, pH 9
(Dako). Endogenous peroxidase was blocked using peroxi-
dase-blocking reagent (Dako) followed by incubation with
primary PTEN antibody clone 6H2.1 (Dako), which
recognizes human and mouse PTEN protein. Incubation
time for primary antibody was 40 minutes in whatever
condition. Secondary EnVision FLEX/HRP (20 minutes) or
FLEX+/HRP (20 + 15 minutes) was used to amplify signal.
Detection was done using 3,3′-diaminobenzidine tetrahy-
drochloride as chromogen (Dako). Slides were counter-
stained with hematoxylin, dehydrated, and mounted.
Appropriate negative controls were also tested, including
same tissues with omission of primary antibody and tumor
samples known to show PTEN silencing.
2.7. Optimization of PTEN IHC
We applied 12 different protocols, resulting from
combination of 3 analytical variables (primary antibody
dilution, primary antibody diluent, and detection method), as
shown in Fig. 1. Three dilutions were selected (1/50, with a
final antibody concentration of 5.85 mg/L, 1/100, with a final
antibody concentration of 2.925 mg/L and 1/150, with a final
antibody concentration of 1.95 mg/L). Evaluation of primary
antibody diluent (FLEX Antibody Diluent, K8006 versus
Dako Antibody Diluent, S3022) and detection method
(EnVision FLEX versus EnVision FLEX+) was also done.
2.8. Preanalytical variables
Samples fixed immediately after surgical resection (b5
minutes) were considered as reference [21] (Fig. 2). Four
different conditions of delayed fixation (30 minutes, 2 hours,
8 hours, and 12 hours) were combined with 3 different
temperature conditions (4°C, room temperature, and 36°C).
Four different time fixation conditions (3, 12, 24, and 72
hours) and 3 different time dehydration conditions (2, 3, and
4 hours) were evaluated. The impact of preanalytical
variables was also assessed in TMA constructed from
matched endometrial aspirates and hysterectomy specimens
from 100 EC patients.
2.9. Assessment of antigen stability after storage
of paraffin blocks
Stability of PTEN antigen was assessed in 3 BC samples
that had been subjected to optimal conditions (fixation time
of b5 minutes). FFPE blocks were stored at different
temperature conditions (4°C, room temperature, and 36°C).
Fig. 1 Analytical variables.
Fig. 2 Preanalytical variables.
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months, and sections were obtained for IHC.
2.10. Scoring of IHC
Two different scoring systems were used and compared
between them. First, we used a histoscore (Hscore) that takes
into consideration the intensity of the staining and the
percentage of positive cells, by applying the formula Hscore =
1× (% light staining) + 2× (%moderate staining) + 3× (% strong
staining). This Hscore ranges from 0 to 300. The reliability of
such scores for the interpretation of IHC staining in TMAs has
been reported previously [26]. A second scoring system was
also used, with the following categories: 0 (negative staining), 1
(lower staining than normal tissue), 2 (staining similar to normal
tissue), and 3 (staining higher than normal tissue). Scoring was
performed by 3 of the authors. Discrepancies were solved by
examining problematic cases under the microscope.
2.11. Statistical analysis
Linear mixed models were used to assess the effects of
any experimental factor on PTEN staining. For each
experimental design, SEs were used to statistically assess
the main effect of each variable but also their paired
interactions. Parametric and nonparametric tests, such as
Student t and Mann-Whitney U tests, were used to study the
association between PTEN IHC expression and the presence
of PTEN genetic alterations. A t test and a Wilcoxon test for
paired data were used to compare PTEN IHC between
endometrial aspirates and hysterectomy specimens. Finally,
the accuracy of PTEN IHC level as predictor for the
presence/absence of genetic alterations was checked after
establishing an optimal cut point, using the same criterion as
the one used for regression models, based on minimizing the
sum of squared residuals. Then, we performed a sensitivity/
specificity analysis to estimate the discriminating ability ofsuch dichotomization and to control false-positive and false-
negative cases. All analyses were performed using the free
package R and a threshold for statistical significance at 0.05.3. Results
3.1. Optimization of PTEN IHC
Staining pattern and intensity of cell cytoplasm and nucleus
as well as background staining were considered. Specific
stainingwas determined as the cytoplasmic and nuclear staining
detected in appropriate cells in the positive control cases and
absent when primary antibody was omitted. Background
staining was the nonspecific staining that was seen in similar
intensity in the different tissue components, including extra-
cellular elements of connective tissue, and also seen in negative
control cases. Results of the effects of the 3 different analytical
variables (primary antibody dilution, primary antibody diluent,
and detection method) are shown in Table 1.
3.1.1. EC and endometrial normal tissue
A significant interaction by linear mixed model was seen
between the detection method and primary antibody
concentration either at the nuclear or at the cytoplasmic
level in EC (P b .0001) and at the cytoplasmic (P = .002) and
nuclear levels (P = .0044) in normal tissue [28]. There was
also an effect of the diluent type on background (P b .0001).
Moreover, the intensity of staining was higher when we used
high concentrations of the antibody in combination with
EnVisionFLEX+ (Supplementary Figures 1 and 2). The
intensity of the nonspecific background staining was lower
when using S3022 diluent (Supplementary Figures 3 and 4).
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At the cytoplasmic and the nuclear levels, there was a
relevant interaction regarding the detection method and the
primary antibody concentration (P = .0009 and P = .007,
respectively, for BC; P b .001 and P = .0004 for normal
tissue). An interaction between type of diluent and the
detection method (P b .0001 both in BC; P b .0001 and
0.00021 in normal tissue) was also observed. Background
staining was dependent on each analytical variable. Staining
increased at high antibody concentration in combination with
the EnVisionFLEX+ (Supplementary Figures 5 and 6).
However, the primary antibody concentration did not
influence staining levels as much as the EnVisionFLEX+
detection method. On the other hand, the staining of the
nucleus and the cytoplasm in BCwas higher whenwe used the
EnVisionFLEX+ method combined with S3022 diluent.
Moreover, statistically significant differences were seen
when different diluents were used, depending on the detection
method and primary antibody concentration that was used.
There were some differences between BC and normal tissue
regarding background staining (Supplementary Figures 7, 8).
However, at the cytoplasmic level in normal tissue, we
observed high Hscores when using S3022 diluent in
combination with EnVisionFLEX+ detection method. ATable 1 Results of the effects of combination of the 3 different anal
Tumor tissue
Cytoplasm Nucleus
Endometrium
Principal effects
Diluent FLEX/S3022 .99 .97
Method FLEX/FLEX+ b.0001 b.0001
Concentration 1/50, 1/100, 1/150 b.0001 b.0001
Interactions
Diluent × method NS NS
Diluent × concentration NS NS
Method × concentration b.0001 b.0001
Breast
Principal effects
Diluent FLEX/S3022 b.0001 .0001
Method FLEX/FLEX+ b.0001 b.0001
Concentration 1/50, 1/100, 1/150 b.0001 b.0001
Interactions
Diluent × method b.0001 b.0001
Diluent × concentration NS NS
Method × concentration .0009 .007
Prostate
Principal effects
Diluent FLEX/S3022 b.0001 .022
Method FLEX/FLEX+ b.0001 b.0001
Concentration 1/50, 1/100, 1/150 b.0001 b.0001
Diluent × method NS b.0001
Diluent × concentration NS .05
Method × concentration NS NS
NOTE. The table is organized according type of tissue (normal tissue or tumor
Abbreviation: NS, nonsignificance.decrease in the intensity background staining in normal tissue
was seen when using S3022 diluent instead of FLEX diluent.
3.1.3. PC and prostatic normal tissue
In tumor tissue, there was an effect of the 3 analytical
variables independently (P b .0001 each variable) at
cytoplasmic level. At nuclear level, there was an interaction
between the detection method and primary antibody diluent
used (P b .001) and a second interaction between the diluent
and primary antibody concentration (P = .05). FLEX diluent
showed lower background than S3022 diluent. Supplementary
Figures 9 and 10 show an increase of the cytoplasmic
immunostaining in an independent manner when using high
primary antibody concentration, S3022 diluent and EnVision-
FLEX+ detection method. At the nuclear level, there was an
increase in staining at high concentrations combined with
FLEX diluent. In normal tissue, 2 statistically significant
interactions were obtained at the cytoplasmic level; first,
combination of primary antibody concentration and the
detection method (P = .04), and second, combination of type
of primary antibody diluent and the detection method (P b
.0001). At the nuclear level, there was an interaction between
primary antibody concentration and the detection method that
was used (P = .003) and a second independent effect regardingytical variables in PTEN immunostaining
Normal tissue
Background Cytoplasm Nucleus Background
b.0001 .56 .56 b.0001
.71 b.0001 b.0001 .47
.54 b.0001 .0002 .0022
NS NS NS NS
NS NS NS NS
NS .002 .044 NS
b.0001 b.0001 .0004 b.0001
b.0001 b.0001 b.0001 .87
.0002 b.0001 b.0001 .22
b.0001 b.0001 b.0021 NS
.0002 NS NS NS
.0005 b.0001 .0004 NS
b.0001 .012 b.0001 b.0001
.77 b.0001 b.0001 .58
.7 b.0001 b.0001 .87
NS b.0001 NS NS
NS NS NS NS
NS .04 .003 NS
tissue) and organ (endometrium, breast, and prostate).
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background level, there was only an effect of primary antibody
diluent (P b .0001). As seen in Supplementary Figures 11 and
12, a positive effect was observed at cytoplasmic level as a
result of an increase of primary antibody concentration in
combination with the EnVisionFLEX+ detection method.
Similarly, a positive effect was seen when combining
EnVisionFLEX+ detection method with S3022 diluent.
Finally, FLEX diluent offered lower background staining
than S3022 diluent in both normal and tumor tissue.
3.1.4. Optimal protocol
In summary, evaluation of the effects of the analytical
variables allowed us to obtain several conclusions: (1)
FLEX diluent was better than S3022 diluent, in terms of
reducing background and improving staining quality
particularly in breast tissue, but the impact in endometrial
and prostatic cells was not significant; (2) the use of the
linker significantly improved the intensity of PTEN staining
by reducing false-negative staining and resulting in a much
better definition of cytoplasmic/nuclear staining. (3) Higher
concentration of primary antibody (1/100 dilution) was
associated with fewer false-negative stains. After optimiza-
tion, the proposed protocol included a high target retrieval
solution (20′), a primary antibody dilution of 1/100, FLEX
diluent, as primary antibody diluent, and EnVision FLEX+
as detection system. Interestingly, FLEX diluent worked
better in prostatic tissue, but S3022 got better staining in
breast and endometrial tissue. This protocol gave the
clearest signal to noise of PTEN immunostaining. Repre-
sentative pictures of staining with the optimal protocol are
seen in Fig. 3.
3.2. Specificity of staining by applying the
optimal protocol
3.2.1. Cell lines
PTEN-positive staining was seen in the HEC as well as in
IK and RL overexpressing PTEN. Negative PTEN staining
was seen in IK, RL, and PTEN shRNA HEC (Supplementary
Figure 13).Fig. 3 Representative pictures of PTEN immunostaining by using3.2.2. Animal model
Tissues from wild-type PTEN mice showed intense
epithelial and stromal staining. Tissues from heterozygous
PTEN+/− mice showed patchy, decreased staining. Tissues
from the conditional, inducible PTEN−/− mice showed
negative staining in epithelial cells with intact expression of
stromal cells (Supplementary Figure 14).
3.2.3. ECs with known molecular status
From the initial series of 33 EC with known molecular
status, only 29 cases were informative (Table 2). The Hscore
of the cases with known PTEN molecular alterations (15
cases) ranged from 0 to 160 (mean Hscore, 34.66), whereas
the Hscore of cases with absence of PTEN molecular
alterations (14 cases) ranged from 0 to 250 (mean Hscore,
119.28) (P = .01).
3.2.4. ECs characterized with SNP arrays
From a series of 32 EC, previously assessed for gains and
losses in the PTEN region, by SNP arrays, 28 cases were
informative. Eight cases showed LOH, 10 cases exhibited
gene polysomy, and 11 cases had no copy number
abnormalities. Tumors with decreased PTEN copy number
had Hscore values that ranged from 0 to 150 (mean, 30),
whereas the Hscore ranged from 0 to 170 (mean, 65) in those
with normal copy number and ranged from 0 to 200 (mean,
66) in those cases with increased copy number. Differences
were not statistically significant (P = .56).
3.3. Effects of preanalytical variables
3.3.1. Delayed fixation combined with temperature
Immunostaining, as assessed by the proposed protocol,
was not influenced by preanalytical variables. The only
factor that showed a mild variation in results was temperature
because there was a trend of significance showing certain
decrease in staining in association with fixation under high
temperature (36°C) (P = .08). The influence of preanalytical
variables in the tumor stroma was higher than in epithelial
cells. Staining in stromal cells was lower when the sample
was subjected to delayed fixation at high temperaturesthe optimal protocol. Magnification ×40, A, EC; B, BC; C, PC.
Table 2 Preanalytical variables
Endometrium Breast Prostate
Tumor
Cytoplasm .08 N.05 N.05
Nucleus N.05 N.05 N.05
Background N.05 N.05 N.05
Stroma
Cytoplasm .001 .001 .003
Nucleus .001 .001 .001
Background N.05 .02 .02
528 O. Maiques et al.(P values around .001 in all cases) (Table 2). Background
nonspecific staining was not modified by any preanalytical
factor (Fig. 4).
3.3.2. Time fixation combined with dehydration in
alcohol absolute
PTEN staining, as assessed by the proposed protocol, did
not show any change in BN, BC, PN, PC, when time of
fixation was modified (Fig. 5). Similar results were obtained
in normal endometrium and EC, although there was a trend
of significance in samples exposed to prolonged dehydration
in alcohol absolute, which showed higher staining, both at
the cytoplasmic and nuclear levels (P = .042 and P = .040,
respectively).
3.3.3. Comparison between matched endometrial
aspirates and hysterectomy specimens
Hscores in the aspirates ranged from 0 to 230 (mean, 80),
whereas in the hysterectomy specimens, Hscores ranged
from 0 to 250 (mean, 40) (P = .002).
3.4. Assessment of antigen stability after storage
There was a statistically significant interaction between
slide storage temperature and time of storage, only when
storage temperature was very high (36°C) (P b .00001, .018,
and .029, respectively). The effect of temperature, time, and
their interaction had statistical significance (P b .00001, .05
and .004, respectively).
3.5. Comparison of 2 different scoring methods
Statistical analysis revealed that the Hscore system
was better than the 4-tiered system in distinguishing
EC with known molecular abnormalities (P = .01 and P =
.92, respectively).4. Discussion
PTEN is a tumor suppressor gene located at 10q23 [1].
PTEN acts as both a lipid and a protein phosphatase. Theformer activity is dephosphorylation of the 3 positions of
phosphatidylinositol 3,4,5-triphosphate, a second messenger
of phosphatidylinositol 3 kinase (PI3K) [2,3]. PTEN antag-
onizes PI3K activity and negatively regulates the PI3K/Akt
pathway [4]. Germline PTEN mutations are found in Cowden
syndrome [22]. PTEN somatic mutations can be detected in a
significant proportion of primary glioblastomas [23,24] as
well as cancers of prostate [15,25], endometrium, or
melanoma [14,26-31]. Occasionally, PTEN mutations have
been reported in sporadic BC (5%) [16], thyroid cancer (7%)
[32], lung cancer (9%), and ovarian cancer (9%) [27]. LOH at
10q23 can be found in approximately 50% of human prostate
cancers, whereas homozygous deletions of PTEN can be
detected in approximately 10% of these cases [15,25]. It has
been questioned whether loss of 1 PTEN allele (haploinsuffi-
ciency) is sufficient for tumorigenesis or whether inactivation
of the second allele might occur through epigenetic rather than
mutational events [33].
A relationship between PTEN status and prognosis has
been proposed in several cancers. In PC, PTEN genomic
deletions have been associated with poor prognosis, and
alternative mechanisms of posttranscriptional down regula-
tion may play a role [34]. Deletion or reduced expression of
PTEN is present in BC. Approximately 50% of patients with
BC harbor a mutation in PTEN or have lost at least 1 copy of
PTEN. In addition, the complete loss of PTEN protein is
more frequent in metastatic than in primary BC [16].
Moreover, a role for PTEN has been proposed as predictor
of response to mammalian target of rapamycin (mTOR) or
phosphoinositide 3-kinase (Pi3K) inhibitors and also in
resistance to HER2 or EGFR inhibitors [11,35]. PTEN is
frequently abnormal in EC. LOH at the PTEN region occurs
in 40% of cases, and somatic mutations, in 37% to 61%. The
prognostic significance of PTEN mutations in EC is
controversial. Several studies have shown that EC with
PTEN mutations has genomic instability [5,29,30].
PTEN function can be altered by genetic mutations, which
result in either a heterozygous or homozygous loss. Epigenetic
silencing, transcriptional repression, micro-RNA regulation,
disruption of competitive endogenous RNA networks, post-
translational modifications, and the aberrant localization of
PTEN can cause subtle or dramatic losses of PTEN function.
Furthermore, numerous PTEN-interacting proteins can posi-
tively or negatively regulate PTEN function [1]. PTEN is not
the only gene abnormal in the PI3K signaling pathway.
Mutations in PIK3CA (p110) and PIK3RI (p85α) have
been detected in some tumors [2,3]. Obviously, alterations of
these genes may be associated with activation of the PI3K
signaling in cases in which PTEN expression is retained.
Accurate identification of functional PTEN loss is
regarded as a possible important parameter in comprehensive
evaluation of tumors, as a potential diagnostic, prognostic,
and predictive biomarker. However, although IHC is seen as
a good method to assess functional PTEN loss in tumors,
there is a general belief that it has been associated with poor
reproducibility. This has, in large part, been due to different
Fig. 4 Impact of preanalytical variables on PTEN staining in EC (delayed fixation and temperature) (×20).
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Fig. 5 Impact of preanalytical variables (time of fixation and alcohol absolute dehydration time) on PTEN staining in prostatic hyperplasia (×20).
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531A protocol for PTEN immunostainingantibodies used, different protocols, various visualization
reagents, and use of manual or automated systems as well as
the variation of scoring systems between studies. However,
to date, mutation analysis has been considered to be the
standard reference for detection of PTEN mutations and
subsequent loss of protein function [6,30]. One of the
possible reasons of poor performance of PTEN IHC in some
series may be the variation in preanalytical variables such as
ischemic time, fixation time, and fixation temperature. Good
performance of an antibody in series of cases with good
control of preanalytical variables does not guarantee a
similar performance in series of cases with different
conditions of delayed fixation or overfixation, unless the
staining protocol is optimized to get similar results in
samples under different preanalytical conditions, as it has
been done in the present study.
In this study, we have developed an optimal protocol for
PTEN IHC, using clone 6H2.1, which, in a previous study of
our group, had better performance in comparison with the
other 3 commercially available antibodies [12]. We decided
to use normal and tumor tissue from 3 different types of
organs (endometrium, breast, and prostate). For validation,
we used 3 cell lines, which were specifically selected as
positive and negative controls. We took also advantage of the
fact that the clone 6H2.1 identifies both the human and the
murine PTEN protein, for using 3 different animal models to
test the results of our protocol. Finally, the protocol was tested
in 2 validation series, composed of EC that had been assessed
for PTEN alterations by different approaches. Afterwards, we
checked the possible influence of preanalytical factors [21].
Finally, we assessed the usefulness of 2 different scoring
systems. Specific attention was given to the impact of
analytical and preanalytical variables to cytoplasmic and
nuclear expression of PTEN. Although initially interpreted as
a cytoplasmic protein, it is now clear that PTEN may be
expressed in the nucleus [12-16]. The ratio of cytoplasmic/
nuclear expression is variable and context specific. It has been
suggested that a high nuclear/cytoplasmic ratio is seen in
normal cells, whereas low nuclear/cytoplasmic ratio is
characteristic of cancer cells [32].
The process of implementing IHC tests in pathology has
been simplified by the availability of standardized reagents,
instruments, and protocols from commercial manufacturers.
Our optimized protocol provides us a better sensitivity
without decreasing specificity. We achieved these results by
establishing criteria for primary antibody dilution (1/100),
primary antibody diluent (FLEX), and detection method
(EnVisionFLEX+), in agreement with the reagents provided
by the manufacturers of the PTEN antibody, clone 6H2.1.
Finally, we observed that the Hscore method combining
intensity of staining and percentage of positive cells provides
the best specificity.
In summary, we have optimized a protocol for PTEN IHC
after having checked the influence of several analytical and
preanalytical variables. Although the protocol provided good
results in samples subjected to different controlled conditionsof delayed fixation and overfixation, differences were seen
when comparing uterine aspirates and matched hysterectomy
specimen, subjected to uncontrolled conditions of delayed
fixation and overfixation. For that reason, it is recommended
that PTEN IHC should be performed in samples subjected to
optimal fixation.Supplementary data
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